Background The optimal time for the initiation of antiretroviral therapy for asymptomatic
patients with human immunodeficiency virus (HIV) infection is uncertain. Methods We …

Background: Optimal timing of antiretroviral therapy (ART) initiation for HIV-infected persons
remains unclear. Objective: To assess survival benefit of initiating ART at different CD4+ cell …

Background Data from randomized trials are lacking on the benefits and risks of initiating
antiretroviral therapy in patients with asymptomatic human immunodeficiency virus (HIV) …

Background. The optimal time to initiate highly active antiretroviral therapy (HAART) remains
unclear. Methods. Five hundred eighty-three human immunodeficiency virus (HIV) …

BACKGROUND: The CD4 cell count at which combination antiretroviral therapy should be
started is a central, unresolved issue in the care of HIV-1-infected patients. In the absence of …

Background Use of antiretroviral treatment for HIV-1 infection has decreased AIDS-related
morbidity and mortality and prevents sexual transmission of HIV-1. However, the best time to …

Objectives: To assess the mortality in a cohort of HIV-infected patients starting highly active
antiretroviral therapy (HAART) compared to the mortality of the general population, focusing …

BACKGROUND: We examined whether the initial virological and immunological response to
highly active antiretroviral treatment (HAART) is prognostic in patients with HIV-1 who start …

Background Insufficient data are available from single cohort studies to allow estimation of
the prognosis of HIV-1 infected, treatment-naive patients who start highly active antiretroviral …

Background Clinical trials have demonstrated that immediate initiation of antiretroviral
therapy (ART) reduces AIDS-related morbidity and mortality. We tested the hypothesis that …